Category Archives: MS Treatment

November 26, 2020 By HSC, Shared Health Study published in U.S. Continue reading →

Clene Nanomedicine is trying to set a new gold standard in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals. The gold nanocrystals are used to amplify bioenergetic reactions in patients in order to drive intracellular biological reactions. Bioenergetic nanotherapeutics are a clean break from pharmaceutical drug development that uses classical synthetic chemistry, Clene Chief Executive Officer Rob Etherington told BioSpace in an interview. Continue reading →

This article was originally published here Neurol Ther. 2020 Nov 23. doi: 10.1007/s40120-020-00223-2 Continue reading →

There are important reasons to study chronic pain and PTSD together, says Matthew J. Bair, MD, MS. Chronic pain and PTSD co-occur frequently.This comorbidity leads to significant adverse effects for patients, and their co-occurrence is worse for patients with only one of these conditions.The comorbidity has negative additive effects on pain and PTSD symptoms, including pain intensity, pain-related disability, worse quality of life, depression, and anxiety, all of which may complicate treatment Continue reading →

Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, discusses how comorbidities affect treatment and options for patients with multiple sclerosis (MS). Continue reading →

November 18, 2020 00:00 ET | Source: Zhittya Genesis Medicine Inc LAS VEGAS, Nov. Continue reading →

A NURSERY teacher who had to remortgage her home to fund treatment to save her life will jet off tomorrow for Mexico. Continue reading →

Long-term follow-up from the phase 3 ORATORIO extension study (ClinicalTrials.gov Identifier: NCT01194570) provided evidence of a consistent, long-term benefit of early and continuous ocrelizumab treatment on disease progression in primary progressive multiple sclerosis (PPMS), according to study results published in the Lancet Neurology. Data from the phase 3 ORATORIO trial supported the safety and efficacy of ocrelizumab for patients with PPMS. The objective of this follow-up study was to evaluate the long-term safety and efficacy of maintaining or switching to ocrelizumab therapy in the open-label extension phase of the trial Continue reading →

CHARLOTTESVILLE, Va. TEPP-46, a new small-molecule drug intended to treat multiple sclerosis, has been considered a promising medicinal option for the disease. A new study giving researchers pause however, after finding TEPP-46 may in actuality make MS worse. Continue reading →

InvestorPlace Eventually, once Donald Trump finally concedes he lost the election, Joe Biden and his transition team can get to work implementing an infrastructure plan that would see the federal government invest $1.3 trillion over the next decade. Its a plan that will help infrastructure stocks across this country. Now before you get all excited that the countrys crumbling infrastructure is going to get a facelift, Donald Trump supposedly had a plan. Continue reading →